Drug development

It is time to drop euphemisms like DNA medicines and gene-based medicines. Gene therapy, says Nuala Moran, has made it through to the commercial mainstream.

Europe has staked its future on building a knowledge economy. But once again, a major R&D investment by one of its leading companies is going to the US.

Scotland is investing £9.5 million of public money in the Swedish stem cell company Cellartis AB to fund an R&D and manufacturing facility in Dundee.

In a rare example of a university tec transfer deal attracting an upfront payment, French pharma company Ipsen paying €1.25 million for a treatment licence.

Industry in Europe and elsewhere will need to act in concert to apply the recommendations iof the report into the disastrous TGN 1412 drugs trial.